BRPI0413008A - espécie de lactobacillus casei, preparação de lactobacilos ativando um corpo vivo tendo uma espécie de lactobacillus casei e, agente preventivo ou terapêutico contra infecções em humanos, animais e plantas tendo uma espécie de lactobacillus casei - Google Patents

espécie de lactobacillus casei, preparação de lactobacilos ativando um corpo vivo tendo uma espécie de lactobacillus casei e, agente preventivo ou terapêutico contra infecções em humanos, animais e plantas tendo uma espécie de lactobacillus casei

Info

Publication number
BRPI0413008A
BRPI0413008A BRPI0413008-1A BRPI0413008A BRPI0413008A BR PI0413008 A BRPI0413008 A BR PI0413008A BR PI0413008 A BRPI0413008 A BR PI0413008A BR PI0413008 A BRPI0413008 A BR PI0413008A
Authority
BR
Brazil
Prior art keywords
species
lactobacillus casei
lactobacillus
lactobacilli
preventive
Prior art date
Application number
BRPI0413008-1A
Other languages
English (en)
Inventor
Tadayo Hata
Hitoshi Toshimori
Toshiyuki Maruoka
Original Assignee
Bhph Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhph Company Ltd filed Critical Bhph Company Ltd
Publication of BRPI0413008A publication Critical patent/BRPI0413008A/pt
Publication of BRPI0413008B1 publication Critical patent/BRPI0413008B1/pt
Publication of BRPI0413008B8 publication Critical patent/BRPI0413008B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"ESPéCIE DE LACTOBACILLUS CASEI, PREPARAçãO DE LACTOBACILOS ATIVANDO UM CORPO VIVO TENDO UMA ESPéCIE DE LACTOBACILLUS CASEI, E AGENTE PREVENTIVO OU TERAPêUTICO CONTRA INFECçõES EM HUMANOS, ANIMAIS E PLANTAS TENDO UMA ESPéCIE DE LACTOBACILLUS CASEI". Foram despendidos esforços para desenvolver um lactobacilo, que seria utilizável como um probiótico, e para desenvolver um lactobacilo que iria colonizar e proliferar em lesões de infecção, eliminando as bactérias causais. Este problema foi resolvido por desenvolvimento de uma espécie de Lactobacillus casei tendo as seguintes propriedades chave: (1) a espécie pode ser cultivada na presença de qualquer um de um a quatro aminoácidos como uma fonte de nitrogênio necessária para crescimento. (2) Quando um meio de cultura promotor do crescimento é inoculado com a espécie e Escherichia coli na mesma contagem e submetido a cultivo misto anaeróbico a 37<198>C, a contagem final de lactobacilos é de 50% ou mais da contagem de coliformes. (3) Quando do cultivo em um meio de cultura apropriado, o valor de pH final é 4,0 ou abaixo, e a maior acidez é 1,5% ou mais. (4) A espécie é resistente a sais de bile a 5%. (5) A espécie produz um antibiótico.
BRPI0413008A 2003-07-30 2004-07-27 preparação de lactobacilos tendo uma espécie de lactobacillus casei ferm bp-10059 (ferm p-19443) e agente preventivo ou terapêutico contra infecções em humanos, animais e plantas tendo uma espécie de lactobacillus casei ferm bp-10059 (ferm p-19443) BRPI0413008B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003203802 2003-07-30
JP2003-203802 2003-07-30
PCT/JP2004/010639 WO2005012503A1 (ja) 2003-07-30 2004-07-27 新規乳酸菌並びに生体賦活型乳酸菌製剤及び生体に対する感染症の予防剤と治療剤

Publications (3)

Publication Number Publication Date
BRPI0413008A true BRPI0413008A (pt) 2006-10-17
BRPI0413008B1 BRPI0413008B1 (pt) 2017-06-20
BRPI0413008B8 BRPI0413008B8 (pt) 2021-05-25

Family

ID=34113630

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413008A BRPI0413008B8 (pt) 2003-07-30 2004-07-27 preparação de lactobacilos tendo uma espécie de lactobacillus casei ferm bp-10059 (ferm p-19443) e agente preventivo ou terapêutico contra infecções em humanos, animais e plantas tendo uma espécie de lactobacillus casei ferm bp-10059 (ferm p-19443)

Country Status (19)

Country Link
US (1) US7863033B2 (pt)
EP (1) EP1661982B1 (pt)
JP (1) JP4661593B2 (pt)
KR (1) KR100763257B1 (pt)
CN (1) CN1842588B (pt)
AT (1) ATE442154T1 (pt)
AU (1) AU2004261832B2 (pt)
BR (1) BRPI0413008B8 (pt)
CA (1) CA2534013C (pt)
DE (1) DE602004023098D1 (pt)
ES (1) ES2332411T3 (pt)
HK (1) HK1095605A1 (pt)
HR (1) HRP20090583T1 (pt)
IN (1) IN2006MU00214A (pt)
MX (1) MXPA06001167A (pt)
RU (1) RU2340669C2 (pt)
UA (1) UA88271C2 (pt)
WO (1) WO2005012503A1 (pt)
ZA (1) ZA200600866B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525633B (zh) * 2009-04-13 2012-01-04 天津科技大学 一种乳杆菌产抗植物致病真菌发酵液的制备方法
JP5612870B2 (ja) * 2010-02-26 2014-10-22 コンビ株式会社 褥瘡改善作用を有する組成物
RU2465322C2 (ru) * 2010-12-09 2012-10-27 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) ШТАММ БАКТЕРИЙ Lactobacillus casei/paracasei - ВГНКИ 10.02.62 ДЕП, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПРИГОТОВЛЕНИЯ ПРОБИОТИЧЕСКОЙ ДОБАВКИ
EP2578088A1 (en) * 2011-10-06 2013-04-10 Nestec S.A. Edible web comprising microorganisms
EP3013150A4 (en) 2013-06-27 2017-03-08 Starbucks Corporation D/b/a Starbucks Coffee Company Biopreservation methods for beverages and other foods
CN104293691B (zh) * 2014-06-13 2017-09-19 杨雄 一株能降低抗药性的嗜酸乳杆菌及其制备的生物制剂
JP5703513B1 (ja) * 2014-11-05 2015-04-22 沖縄ハム総合食品株式会社 新規乳酸菌株及びその乳酸菌株による発酵組成物及び醗酵エキス
CN105362297B (zh) * 2015-09-22 2019-03-08 福建贝迪药业有限公司 一种用于防控雏禽肠道病原的复合微生态制剂及其制备方法
US10363279B2 (en) * 2016-02-20 2019-07-30 Nubiome, Inc. Treatment and prophylaxis for neurological conditions and diseases
BE1024189B1 (nl) 2016-10-28 2017-12-05 Yun NV Spuitbus met bacteriële species
JP7228200B2 (ja) 2017-03-23 2023-02-24 ユニバーシタット アントウェルペン 新規のプロバイオティックなラクトバチルス・カゼイ株及びその使用
WO2019216438A1 (ja) * 2018-05-11 2019-11-14 株式会社セルテクノロジー 間葉系細胞の培養上清を含む歯周病治療剤
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4716791B1 (pt) * 1968-10-20 1972-05-17
JPS52102419A (en) * 1976-02-23 1977-08-27 Seikenkai Lactic acid producing bacillus preparation
GB1585863A (en) 1977-08-24 1981-03-11 Seiken Kai Foundational Juridi Pharmaceutical lactobacillus preparations
FR2400901A1 (fr) 1977-08-26 1979-03-23 Seiken Kai Foundational Juridi Preparations pharmaceutiques de lactobacillus, utiles notamment comme anti-infectieux
DE2738652C3 (de) 1977-08-26 1981-02-19 Seiken Kai Foundation Juridical Person, Tondabayashi, Osaka (Japan) Lactobacillus-Präparat und seine Verwendung bei der Bekämpfung bakterieller Infektionen und Entzündungen
US4579740A (en) * 1983-07-11 1986-04-01 Microlife Technics, Inc. Fermentation method using a selected lactobacillus
JP3958456B2 (ja) * 1998-12-25 2007-08-15 高梨乳業株式会社 血清脂質改善効果を有する機能性飲食品
JP2000217566A (ja) * 1999-01-25 2000-08-08 Bhph Co Ltd ラクトバチラスクリアランスを培養するための培養基および該菌種の保存方法
JP4193269B2 (ja) * 1999-03-04 2008-12-10 ビーエイチピーエイチ カンパニーリミテッド 新規な生体浄化活性型乳酸菌製剤
EP1038951A1 (en) 1999-03-23 2000-09-27 Societe Des Produits Nestle S.A. Synthetic medium for cultivating lactobacillus and/or bifidobacteria
ES2226228T5 (es) 1999-04-30 2009-01-16 Societe Des Produits Nestle S.A. Crecimiento mejorado de las bacterias del acido lactico en la leche.
JP4193330B2 (ja) * 2000-05-24 2008-12-10 ビーエイチピーエイチ カンパニーリミテッド 新規な感染症対応型乳酸菌および該乳酸菌を主成分とした乳酸菌製剤
KR100419132B1 (ko) * 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
JP4528472B2 (ja) * 2001-11-29 2010-08-18 ビオフェルミン製薬株式会社 歯周病の予防または治療剤

Also Published As

Publication number Publication date
WO2005012503A1 (ja) 2005-02-10
CN1842588B (zh) 2010-09-29
EP1661982A4 (en) 2007-03-14
JPWO2005012503A1 (ja) 2007-09-27
KR100763257B1 (ko) 2007-10-04
ZA200600866B (en) 2007-04-25
HK1095605A1 (en) 2007-05-11
MXPA06001167A (es) 2006-10-30
UA88271C2 (uk) 2009-10-12
BRPI0413008B8 (pt) 2021-05-25
RU2340669C2 (ru) 2008-12-10
IN2006MU00214A (pt) 2007-06-15
HRP20090583T1 (hr) 2009-12-31
JP4661593B2 (ja) 2011-03-30
BRPI0413008B1 (pt) 2017-06-20
ES2332411T3 (es) 2010-02-04
EP1661982A1 (en) 2006-05-31
RU2006106279A (ru) 2006-08-27
CA2534013C (en) 2010-11-02
US7863033B2 (en) 2011-01-04
EP1661982B1 (en) 2009-09-09
ATE442154T1 (de) 2009-09-15
AU2004261832B2 (en) 2007-10-04
AU2004261832A1 (en) 2005-02-10
DE602004023098D1 (de) 2009-10-22
US20080293126A1 (en) 2008-11-27
CN1842588A (zh) 2006-10-04
CA2534013A1 (en) 2005-02-10
KR20060037412A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
HK1095605A1 (en) Novel lactobacillus, living body activating lactobacillus preparation and preventive or therapeutic agent against living body infection
BR0213189A (pt) Composição compreendendo uma cepa lactobacillus pentosus e usos da mesma
CA2503130A1 (en) Antimicrobial compounds from bacillus subtilis for use against animal and human pathogens
WO2004030624A3 (en) Compositions and methods for inhibiting pathogenic growth
NO20053462L (no) Ernaeringsformulering surgjort med melkesyre
EP3464609A1 (en) Method for producing microbial probiotic biofilms and uses thereof
DE60123986D1 (de) Verwendung eines mittels zur verbesserung des knochenmetabolismus
MX2022014451A (es) Bacterias de acido lactico bioprotectoras con baja posacidificacion.
del Pozo et al. Granulicatella adiacens breast implant-associated infection
Goudarzi et al. evaluation of antimicrobial activity of probiotic lactobacillus strains against growth and urease activity of proteus spp.
Prol‐García et al. Phaeobacter grown in biofilters: A new strategy for the control of Vibrionaceae in aquaculture
Sharma et al. Bacteriological analysis of bile culture from a tertiary care hospital
Sękowska et al. New species of bacteria in human infections
Rajaraman et al. Effect of hen egg white on microbial adhesion and biofilm growth of biomaterial associated infection causing pathogens
Laiche et al. Study of the antimicrobial activity of Bactericocins produced by lactic bacteria isolated from camel milk in southern Algeria
Al-Mathkhury et al. Probiotic effect of lactobacilli on mice incisional wound infections
RU2393214C1 (ru) Иммунобиологическое противоаллергическое средство (варианты), штамм lactobacillus acidophilus nkjc, штамм lactobacillus acidophilus jch, штамм lactobacillus acidophilus kaa
Chae-Woo et al. Physiological characterization of Lactobacillus sp. JK-8 isolated from shrimp aquaculture pond
SK289178B6 (sk) Kmeň mikroorganizmov Weissella cibaria 4/8 D37 CCM 9015, bakteriálna kultúra, bezbunkový supernatant kmeňa a farmaceutická kompozícia obsahujúca tento kmeň
Mishra et al. Isolation and characterization of probiotic microorganism from fermented dairy products
Alipin et al. The potential of indigenous lactic acid bacteria against Salmonella sp.
Yazici et al. Phenotypic characterization and antibiotic susceptibilities of ewingella americana and kluyvera intermedia isolated from soaked hides and skins
Fahad et al. Effect of Lactobacillus acidophilus on Escherichia coli causing urinary tract infections in vitro and in vivo
Hassan Evaluation Activity of S-Layer Proteins and Filtrate of Lactobacillus Spp. against Some Pathogenic Microorganisms In Vitro
Hadid et al. Treatment of bacteria causing burn wound infections by Lactobacillus Reuteri as a probiotic

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REF. RPI 2358 DE 15/03/2016 - DESPACHO 7.7 - NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI, POR TER SIDO INDEVIDO, UMA VEZ QUE, CONFORME OFICIO 209/16/COOPI/GGMED/ANVISA DE 17/11/2016, FOI IDENTIFICADO UM EQUIVOCO NO ENCAMINHAMENTO DE PARECER.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.